Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752–6.

Article  PubMed  Google Scholar 

Dinah C, Enoch J, Ghulakhszian A, Taylor DJ, Crabb DP. Intravitreal treatment for geographic atrophy: coming soon to a patient near you? Eye. 2021;36:1121–3.

Article  PubMed  PubMed Central  Google Scholar 

Varma R, Souied EH, Tufail A, Tschosik E, Ferrara D, Zhang J, et al. Maximum reading speed in patients with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2018;59:195–201.

Article  Google Scholar 

Krezel AK, Hogg R, Lohfeld L, Chakravarthy U, Azuara-Blanco A. Core outcomes for geographic atrophy trials. Br J Ophthalmol. 2020;104:1196–202.

PubMed  Google Scholar 

Lally DR, Heier JS, Sadda S, Eichenbaum DA & Danzig C Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study. 2022. https://investors.ivericbio.com/static-files/4341199c-b031-45a0-bc6f-a032a44a8021 [cited 2022 Sep 1].

Heier J, Singh R, Wykoff C, Steinle N, Boyer D, Monés J, et al. Efficacy of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the phase 3 OAKS and DERBY trials. In 2022 [cited 2022 Nov 28]. Available from: https://investors.apellis.com/static-files/78d1b209-7324-4c4c-8b20-bf7778493bae.

Loewenstein A, Trivizki O. Future perspectives for treating patients with geographic atrophy. Graefe’s Arch Clin Exp Ophthalmol. 2022. https://doi.org/10.1007/s00417-022-05931-z.

Article  Google Scholar 

Hutton D. Industry leaders react to FDA’s pegcetacoplan approval. Ophthalmology Times [Internet]. 2023; Available from: https://www.ophthalmologytimes.com/view/industry-leaders-react-to-fda-s-pegcetacoplan-approval.

Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: Non-adherence and non-persistence in intravitreal treatment. Graefe’s Arch Clin Exp Ophthalmol. 2020;258:2077–90.

Article  Google Scholar 

Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefe’s Arch Clin Exp Ophthalmol. 2013;251:1281–4.

Article  CAS  Google Scholar 

Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294.

Article  PubMed  PubMed Central  Google Scholar 

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127–40.

Article  PubMed  Google Scholar 

Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration: a review. Graefe’s Arch Clin Exp Ophthalmol. 2016;254:1873–80.

Article  CAS  Google Scholar 

Thier A, Holmberg C. The patients’ view: age-related macular degeneration and its effects–a meta-synthesis. Disabil Rehabil. 2022;44:661–71.

Article  PubMed  Google Scholar 

Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125:369–90.

Article  PubMed  Google Scholar 

Colijn JM, Liefers B, Joachim N, Verzijden T, Meester-Smoor MA, Biarnés M, et al. Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139:743–50.

Article  PubMed  PubMed Central  Google Scholar 

Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:88.

Article  PubMed  PubMed Central  Google Scholar 

Klaic M, Kapp S, Hudson P, Chapman W, Denehy L, Story D, et al. Implementability of healthcare interventions: An overview of reviews and development of a conceptual framework. Implement Sci. 2022;17:1–20.

Article  Google Scholar 

Klassen AC, Creswell J, Plano Clark VL, Smith KC, Meissner HI. Best practices in mixed methods for quality of life research. Qual Life Res. 2012;21:377–80.

Article  PubMed  Google Scholar 

Enoch J, Ghulakhszian A, Crabb DP, Dinah C, Taylor DJ. Acceptability of intravitreal injections in geographic atrophy: Protocol for a mixed-methods pilot study. BMJ Open. 2021;11:e049495.

Article  PubMed  PubMed Central  Google Scholar 

Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: A randomized phase 2 trial. Ophthalmology. 2020;127:186–95.

Article  PubMed  Google Scholar 

Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, et al. C5 inhibitor Avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128:576–86.

Article  PubMed  Google Scholar 

Freeman WR, Bandello F, Souied EH, Guymer RH, Garg S, Chen FK, et al. Phase 2b Study of Brimonidine DDS: Potential novel treatment for geographic atrophy. Invest Ophthalmol Vis Sci. 2019;60:971.

Google Scholar 

UK Government. Regional ethnic diversity [Internet]. 2020 [cited 2022 Sep 9]. Available from: https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/regional-ethnic-diversity/latest.

Sandelowski M. Sample size in qualitative research. Res Nurs Health. 1995;18:179–83.

Article  CAS  PubMed  Google Scholar 

Holz FG, Ho A, Khanani AM, Chang A, Bliss C, Sharp D, et al. Efficacy of Pegcetacoplan in subgroups defined by distance from the foveal center point in the phase 3 OAKS and DERBY studies of patients with geographic atrophy. In: The Macula Society 45th Annual Meeting, Berlin, Germany. 2022. Available from: https://investors.apellis.com/static-files/adcd2696-44f6-41f2-bbb8-4cb517cdd67c [cited 2022 Sep 13].

Richardson SJ, Carroll CB, Close J, Gordon AL, O’Brien J, Quinn TJ, et al. Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities. Age Ageing. 2020;49:901–6.

Article  PubMed  Google Scholar 

Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Analysing qualitative data. (Routledge, London, 1994) 173–94.

Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.

Article  PubMed  PubMed Central  Google Scholar 

Guest G, MacQueen KM, Namey EE. Applied Thematic Analysis. (Sage, Thousand Oaks, 2012).

Künzel SH, Möller PT, Lindner M, Goerdt L, Nadal J, Schmid M, et al. Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61:63.

Article  PubMed  PubMed Central  Google Scholar 

Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, et al. Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16. Ophthalmology. 2018;125:1913–28.

Article  PubMed  Google Scholar 

Goldberg R, Heier J, Wykoff CC, Staurenghi G, Singh RP, Steinle N, et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. 2022. https://investors.apellis.com/static-files/ed761716-e969-4d23-a352-541fa01fd557 [cited 2022 Aug 31].

Sadda SR, Sarraf D. Therapeutic Margin for Geographic Atrophy: The Race Between Longevity and Disease Progression. JAMA Ophthalmol. 2021;139:751–2.

Article  PubMed  Google Scholar 

Singh RP, Boyer DS, Lad EG, Holz FG, Bliss C, Wong JG, et al. Efficacy of Intravitreal Pegcetacoplan in Geographic Atrophy: 24-Month Results from the Phase 3 OAKS and DERBY Trials. 2022. https://investors.apellis.com/static-files/a1ec9fdb-ef70-49c1-ae6e-5ad7caa63abe [cited 2022 Oct 24].

Iveric Bio. Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy [Internet]. Parsippany, New Jersey; 2022 Sep [cited 2022 Sep 9]. Available from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-positive-topline-data-zimurar-gather2-phase.

Bouaziz M, Cheng T, Minuti A, Denisova K, Barmettler A. Shared decision making in ophthalmology: A scoping review. Am J Ophthalmol. 2021;237:146–53.

Article  PubMed  Google Scholar 

Scheffer M, Menting J, Roodbeen R, van Dulmen S, van Hecke M, Schlingemann R, et al. Patients’ and health professionals’ views on shared decision‐making in age‐related macular degeneration care: A qualitative study. Ophthalmic Physiol Opt. 2022;42:1015–22.

Article  PubMed  Google Scholar 

Taylor DJ, Jones L, Binns AM, Crabb DP. ‘You’ve got dry macular degeneration, end of story’: A qualitative study into the experience of living with non-neovascular age-related macular degeneration. Eye. 2020;34:461–73.

Article  PubMed  Google Scholar 

Carlton J, Barnes S, Haywood A. Patient Perspectives in Geographic Atrophy (GA): Exploratory qualitative research to understand the impact of GA for patients and their families. Br Ir Orthopt J. 2019;15:133.

Article  PubMed  PubMed Central  Google Scholar